AU2007269245B2 - Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells - Google Patents

Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells Download PDF

Info

Publication number
AU2007269245B2
AU2007269245B2 AU2007269245A AU2007269245A AU2007269245B2 AU 2007269245 B2 AU2007269245 B2 AU 2007269245B2 AU 2007269245 A AU2007269245 A AU 2007269245A AU 2007269245 A AU2007269245 A AU 2007269245A AU 2007269245 B2 AU2007269245 B2 AU 2007269245B2
Authority
AU
Australia
Prior art keywords
cells
cancer
carcinoma
cell
dendritic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007269245A
Other languages
English (en)
Other versions
AU2007269245A1 (en
Inventor
Jacques F. Banchereau
Susan Burkeholder
Anna Karolina Palucka
Nicolas Taquet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of AU2007269245A1 publication Critical patent/AU2007269245A1/en
Application granted granted Critical
Publication of AU2007269245B2 publication Critical patent/AU2007269245B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2007269245A 2006-06-30 2007-06-29 Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells Ceased AU2007269245B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81791606P 2006-06-30 2006-06-30
US60/817,916 2006-06-30
PCT/US2007/072525 WO2008005859A2 (en) 2006-06-30 2007-06-29 Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells

Publications (2)

Publication Number Publication Date
AU2007269245A1 AU2007269245A1 (en) 2008-01-10
AU2007269245B2 true AU2007269245B2 (en) 2012-04-12

Family

ID=38895372

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007269245A Ceased AU2007269245B2 (en) 2006-06-30 2007-06-29 Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells

Country Status (8)

Country Link
US (1) US20080031900A1 (enExample)
EP (2) EP2037957A4 (enExample)
JP (3) JP2009542714A (enExample)
KR (1) KR20090033375A (enExample)
CN (1) CN101511384A (enExample)
AU (1) AU2007269245B2 (enExample)
CA (1) CA2691346A1 (enExample)
WO (1) WO2008005859A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149382A2 (en) * 2008-06-06 2009-12-10 Baylor Research Institute Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
KR20140054140A (ko) * 2011-07-27 2014-05-08 베일러 리서치 인스티튜트 췌장암에 대한 수지상 세포(ｄｃ) - 백신 치료요법
SG11201401631VA (en) * 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine with gamma interferon
EP2591798B1 (en) 2011-11-09 2014-11-19 Werner Lubitz Vaccine for use in tumor immunotherapy
CN112646778A (zh) * 2012-12-28 2021-04-13 阿姆弗拉公司 免疫原性裂解物制备方法、获得的裂解物、负载有该裂解物的树突状细胞以及药物组合物
EP2787005A1 (en) 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
JP6967963B2 (ja) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
SG11201701728PA (en) * 2014-09-04 2017-04-27 Agency Science Tech & Res A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
WO2016064899A1 (en) * 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
WO2016148179A1 (ja) * 2015-03-17 2016-09-22 国立大学法人信州大学 Ｉｆｎを用いた非接着培養による樹状細胞の調製方法
JP7019578B2 (ja) * 2015-12-30 2022-02-15 セルジーン コーポレイション Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
CN108567977B (zh) * 2017-03-13 2022-04-12 复旦大学 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
KR20190057938A (ko) 2017-11-21 2019-05-29 이근량 버스닥트의 다점 온도감지 및 광학적 경보시스템
CA3087418A1 (en) * 2018-01-18 2019-07-25 University Of South Florida Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
WO2019204391A1 (en) * 2018-04-19 2019-10-24 Robert Caruso Cryo-inactivated cancer cells for cancer immunotherapy
WO2020180648A1 (en) * 2019-03-01 2020-09-10 Gritstone Oncology, Inc. Selection of t cell receptors
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP7859015B2 (ja) * 2021-07-15 2026-05-15 大日本印刷株式会社 細胞医薬品の提供方法
KR20250110348A (ko) 2022-11-23 2025-07-18 제이제이알앤디 엘엘씨 암 세포독성 엑소좀 제형 및 암 치료에 사용되는 방법
WO2024256477A1 (en) * 2023-06-13 2024-12-19 Pdc Line Pharma Sa Method for preparing plasmacytoid dendritic cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140983A1 (en) * 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT633929E (pt) * 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE69839215T2 (de) 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
CA2318557A1 (en) * 1998-01-16 1999-07-22 Biomira Usa Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
CA2542686A1 (en) * 2003-10-15 2005-05-06 Istituto Superiore Di Sanita Colorectal cancer antigen
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20060045883A1 (en) * 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140983A1 (en) * 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies

Also Published As

Publication number Publication date
AU2007269245A1 (en) 2008-01-10
CA2691346A1 (en) 2008-01-10
KR20090033375A (ko) 2009-04-02
EP2630968A1 (en) 2013-08-28
EP2037957A2 (en) 2009-03-25
JP2009542714A (ja) 2009-12-03
JP2016041725A (ja) 2016-03-31
CN101511384A (zh) 2009-08-19
EP2037957A4 (en) 2010-09-08
JP2013177430A (ja) 2013-09-09
WO2008005859A2 (en) 2008-01-10
WO2008005859A3 (en) 2008-11-20
JP6134763B2 (ja) 2017-05-24
US20080031900A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
JP6134763B2 (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
Reardon et al. The development of dendritic cell vaccine-based immunotherapies for glioblastoma
Palucka et al. Dendritic cells: a critical player in cancer therapy?
AU722328B2 (en) Methods for generating cytotoxic T cells in vitro
US20080112962A1 (en) Dendritic Cells Loaded with Heat Shocked Melanoma Cell Bodies
US20080171023A1 (en) Method to increase class i presentation of exogenous antigens by human dendritic cells
CN102933228A (zh) 制备和储存活化的、成熟树突细胞的体系和方法
AU2001259760A1 (en) Method to increase class I presentation of exogenous antigens by human dendritic cells
EP3350318B1 (en) Methods relating to activated dendritic cell compositions for subjects with advanced cancers
Quah et al. The application of dendritic cell-derived exosomes in tumour immunotherapy
Wang et al. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes
Pilon-Thomas et al. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells
Dworacki et al. Unpulsed dendritic cells induce broadly applicable anti-tumor immunity in mice
Sanchez et al. T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas
Paglia et al. Presentation of tumor antigens: The role of dendritic cells
HK1161977B (en) Method to increase class i presentation of exogenous antigens by human dendritic cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired